
Conference Coverage
Latest Content

Azathioprine Use Linked to Increased Squamous Cell Carcinoma Risk in Organ Transplant Recipients

FAQ: How Long COVID Is Defined, Diagnosed, and Managed in 2026

Less-Efficient ACOs Entering Medicare Shared Savings Program More Likely to Earn Bonuses

FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant NSCLC

Equity and Innovation in Value-Based Precision Oncology: A Q&A With Tina Bhatnagar, DO

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Emerging CRC diagnostic tools along with better public awareness could help reverse rising deaths in younger adults, says Jordan Karlitz, MD.

Artificial intelligence is emerging as a powerful tool for improving the diagnosis, phenotyping, and treatment of inflammatory skin diseases such as alopecia.

Machine learning–based risk prediction models, particularly gradient boosting, can accurately identify early clinical indicators of CKD.

Elevance Health's Shane Hochradel explains how the company tracks provider satisfaction and uses AI to cut administrative burden.

Employers use carve-outs and cash-pay channels to reduce GLP-1 costs, while Scripta’s Navigator helps members compare prices and find support.

A prospective study of first-degree relatives of patients with MS found that this high-risk population faces significantly elevated incidence rates and has strong willingness to participate in prevention trials.

Mitochondrial DNA heteroplasmy is independently associated with an increased risk of CLL, suggesting potential as a novel biomarker for early risk identification.

Presentations focused on the efficacy of long-acting cabotegravir, doravirine/islatravir, and bictegravir/lenacapavir when used as antiretroviral therapy.

MASLD and type 2 diabetes are closely interconnected conditions driven by shared metabolic dysfunction that together increase the risk of liver disease progression, cardiovascular complications, and mortality.

CAB+RPV LA Is Versatile, Preferred in Treatment-Naive Patients
Abstracts presented during the Conference on Retroviruses and Opportunistic Infections 2026 offered a glimpse into which therapies patients prefer to use to treat HIV.




































